ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA SAN DIEGO, June 10, 2024 (Korea Bizwire) – In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: [...]
Justin Leong appointed Chief Product Officer, effective immediately. Katrin Pucknat appointed Chief Marketing Officer, effective immediately. Mike Fliss appointed Chief Revenue Officer, effective immediately. Rob Douglas, President and Chief Operating Officer, to retire January 1, 2024. SAN DIEGO, Nov. 09 (Korea Bizwire) — ResMed (NYSE: RMD, ASX: RMD) today announced a new operating model to [...]
SAN DIEGO, July 5 (Korea Bizwire) — ResMed (NYSE: RMD, ASX: RMD) today announced the acquisition of privately held Somnoware, a U.S. leader in sleep and respiratory care diagnostics software. Somnoware software streamlines the processes of physicians as well as sleep and pulmonary function testing labs for diagnosing and evaluating a patient’s sleep and respiratory [...]
INDIANAPOLIS, June 8 (Korea Bizwire) — People with heart failure and obstructive sleep apnea (OSA) can significantly reduce hospitalizations and ER visits as well as related costs by being adherent on positive airway pressure (PAP) therapy, according to two studies supported by ResMed (NYSE: RMD, ASX: RMD) and presented at SLEEP 2023. Key Results One [...]
France’s Jean-Louis Pépin and Germany’s Holger Woehrle presented studies in which treating OSA with CPAP lowered all-cause mortality for PAP vs. non-PAP users with OSA Germany’s Michael Arzt presented new evidence that treating CSA with ASV* caused “a significant and clinically relevant improvement in disease-specific QoL, daytime sleepiness, and quality of sleep” WASHINGTON, May 25 (Korea [...]
SAN DIEGO, May 2 (Korea Bizwire) — ResMed (NYSE: RMD, ASX: RMD) today announced the appointment of two new executive team members: Michael Rider, Global General Counsel & Secretary, effective July 1, 2023, and Dawn Haake as ResMed’s first Chief Quality Officer, effective May 1, 2023. Both joined ResMed’s executive team on May 1 and [...]
SAN DIEGO, March 30 (Korea Bizwire) — ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023. He will remain in a consulting role with ResMed through December 31, 2023. ResMed will conduct an internal search for the successor to [...]
SAN DIEGO, March 13 (Korea Bizwire) — ResMed (NYSE: RMD, ASX: RMD) announced today the results from its 2023 Global Sleep Survey in conjunction with National Sleep Awareness Week (March 12-18) and World Sleep Day (March 17) to raise awareness for the importance of sleep as a key component of physical and mental health. The [...]
SAN DIEGO, Jan. 26 (Korea Bizwire) — ResMed (NYSE: RMD, ASX: RMD) today announced ResMed’s board of directors has appointed chief executive officer Michael (“Mick”) Farrell as chair of the board, effective January 25, 2023. Mr. Farrell succeeds current chair Peter Farrell who will become chair emeritus and will remain an active board member. Mick [...]
SAN DIEGO and HILDESHEIM, Germany, Nov. 22 (Korea Bizwire) — ResMed (NYSE: RMD, ASX: RMD) today announced it has completed its €958.6 million acquisition of MEDIFOX DAN, a German leader in software solutions for a wide variety of out-of-hospital care providers. MEDIFOX DAN is headquartered in Hildesheim, Germany, with over 700 employees. It now operates [...]